The acute kidney injury treatment market has been growing rapidly due to the increasing prevalence of chronic kidney diseases globally. Acute kidney injury, also known as acute renal failure, is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. It involves the rapid loss of the kidney’s ability to remove waste and help balance fluids and electrolytes in the body. The treatment options for acute kidney injury include dialysis, intravenous fluids, and medication. Dialysis is the most common treatment method used in severe kidney injury cases to help filter waste and excess fluid from the blood.

The global acute kidney injury treatment market is estimated to be valued at US$ 1,857.8 million in 2021 and is expected to exhibit a CAGR of 7.2% during the forecast period (2021-2028).

Key Takeaways
Key players operating in the acute kidney injury treatment market are Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., and Asahi Kasei Medical Co.

The growing prevalence of chronic diseases such as diabetes and high blood pressure that can potentially lead to acute kidney injury is expected to drive the Acute Kidney Injury Treatment Market Demand. According to the Centers for Disease Control and Prevention, over 30 million Americans currently have diabetes and additional 84 million have prediabetes.

Geographically, North America is expected to dominate the global market due to growing incidences of acute kidney injury, rise in aging population, and advanced healthcare infrastructure. However, Asia Pacific region is likely to exhibit fastest growth over the forecast period owing to increasing healthcare spending and growing awareness.

Get More Insights on- Acute Kidney Injury Treatment Market